New

Abiomed

The AI engine Fit Assessment

Beta

The company will be attending ViVE 2025 Event

Blurb

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients.

HQ Location

Danvers (United States)

Founded

1981

Employees

1001 - 5000

Total funding raised

$16.60B

Last Funding Event

Acquired by Johnson & Johnson, November 2022

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M

Developer of medical devices that provides circulatory and respiratory support by enabling the heart to rest and recover by improving blood flow and temporarily assisting with the pumping function. The company offers temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.